Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5160c99c6dc74e998f952d3b03d4f787 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5160c99c6dc74e998f952d3b03d4f787 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5160c99c6dc74e998f952d3b03d4f7872021-11-22T09:00:06ZMulticenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence10.1136/jitc-2021-0032722051-1426https://doaj.org/article/5160c99c6dc74e998f952d3b03d4f7872021-10-01T00:00:00Zhttps://jitc.bmj.com/content/9/10/e003272.fullhttps://doaj.org/toc/2051-1426Omid HamidBrendan CurtiCraig L SlingluffMohammed MilhemJose LutzkySuthee RapisuwonBrian GastmanTakami SatoMarcus O ButlerRobert AndtbackaEddy HsuehRobert WeberJohn GlaspySekwon JangSajeve ThomasKarl D LewisLeonel Hernandez-AyaJohn HyngstromAdam BergerEdward LevineMontaser F ShaheenVinay GuptaSvetomir N MarkovicTawnya BowlesJoel ClaveauPrejesh PhilipsShernan G HoltanWilliam SchmidtJuan ParamoArvinda PadmanabhanDaniel MiltonAndrew PecoraSuprith BadarinathJohn KeechSujith KalmadiPallavi KumarAnna BarJ Thaddeus BeckJeffrey B TraversCatalin MihalcioiuPeter BeitschEdward C McCarronDeepti BehlBrent BlumensteinJoanna J PeterkinBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Omid Hamid Brendan Curti Craig L Slingluff Mohammed Milhem Jose Lutzky Suthee Rapisuwon Brian Gastman Takami Sato Marcus O Butler Robert Andtbacka Eddy Hsueh Robert Weber John Glaspy Sekwon Jang Sajeve Thomas Karl D Lewis Leonel Hernandez-Aya John Hyngstrom Adam Berger Edward Levine Montaser F Shaheen Vinay Gupta Svetomir N Markovic Tawnya Bowles Joel Claveau Prejesh Philips Shernan G Holtan William Schmidt Juan Paramo Arvinda Padmanabhan Daniel Milton Andrew Pecora Suprith Badarinath John Keech Sujith Kalmadi Pallavi Kumar Anna Bar J Thaddeus Beck Jeffrey B Travers Catalin Mihalcioiu Peter Beitsch Edward C McCarron Deepti Behl Brent Blumenstein Joanna J Peterkin Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence |
| format |
article |
| author |
Omid Hamid Brendan Curti Craig L Slingluff Mohammed Milhem Jose Lutzky Suthee Rapisuwon Brian Gastman Takami Sato Marcus O Butler Robert Andtbacka Eddy Hsueh Robert Weber John Glaspy Sekwon Jang Sajeve Thomas Karl D Lewis Leonel Hernandez-Aya John Hyngstrom Adam Berger Edward Levine Montaser F Shaheen Vinay Gupta Svetomir N Markovic Tawnya Bowles Joel Claveau Prejesh Philips Shernan G Holtan William Schmidt Juan Paramo Arvinda Padmanabhan Daniel Milton Andrew Pecora Suprith Badarinath John Keech Sujith Kalmadi Pallavi Kumar Anna Bar J Thaddeus Beck Jeffrey B Travers Catalin Mihalcioiu Peter Beitsch Edward C McCarron Deepti Behl Brent Blumenstein Joanna J Peterkin |
| author_facet |
Omid Hamid Brendan Curti Craig L Slingluff Mohammed Milhem Jose Lutzky Suthee Rapisuwon Brian Gastman Takami Sato Marcus O Butler Robert Andtbacka Eddy Hsueh Robert Weber John Glaspy Sekwon Jang Sajeve Thomas Karl D Lewis Leonel Hernandez-Aya John Hyngstrom Adam Berger Edward Levine Montaser F Shaheen Vinay Gupta Svetomir N Markovic Tawnya Bowles Joel Claveau Prejesh Philips Shernan G Holtan William Schmidt Juan Paramo Arvinda Padmanabhan Daniel Milton Andrew Pecora Suprith Badarinath John Keech Sujith Kalmadi Pallavi Kumar Anna Bar J Thaddeus Beck Jeffrey B Travers Catalin Mihalcioiu Peter Beitsch Edward C McCarron Deepti Behl Brent Blumenstein Joanna J Peterkin |
| author_sort |
Omid Hamid |
| title |
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence |
| title_short |
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence |
| title_full |
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence |
| title_fullStr |
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence |
| title_full_unstemmed |
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence |
| title_sort |
multicenter, double-blind, placebo-controlled trial of seviprotimut-l polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence |
| publisher |
BMJ Publishing Group |
| publishDate |
2021 |
| url |
https://doaj.org/article/5160c99c6dc74e998f952d3b03d4f787 |
| work_keys_str_mv |
AT omidhamid multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT brendancurti multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT craiglslingluff multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT mohammedmilhem multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT joselutzky multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT sutheerapisuwon multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT briangastman multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT takamisato multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT marcusobutler multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT robertandtbacka multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT eddyhsueh multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT robertweber multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT johnglaspy multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT sekwonjang multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT sajevethomas multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT karldlewis multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT leonelhernandezaya multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT johnhyngstrom multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT adamberger multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT edwardlevine multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT montaserfshaheen multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT vinaygupta multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT svetomirnmarkovic multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT tawnyabowles multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT joelclaveau multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT prejeshphilips multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT shernangholtan multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT williamschmidt multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT juanparamo multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT arvindapadmanabhan multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT danielmilton multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT andrewpecora multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT suprithbadarinath multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT johnkeech multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT sujithkalmadi multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT pallavikumar multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT annabar multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT jthaddeusbeck multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT jeffreybtravers multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT catalinmihalcioiu multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT peterbeitsch multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT edwardcmccarron multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT deeptibehl multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT brentblumenstein multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence AT joannajpeterkin multicenterdoubleblindplacebocontrolledtrialofseviprotimutlpolyvalentmelanomavaccineinpatientswithpostresectionmelanomaathighriskofrecurrence |
| _version_ |
1718417794170617856 |